p
ITUITARY adenomas are by definition benign tumors. Surgical experience, however, shows that this is not necessarily true. Depending on tumor size, up to 85% grow invasively into the surrounding structures. 7"~~ Invasion may be microscopic or can produce large tumor masses. Conventional cytological characteristics (hypercellularity; variations in nuclear size, shape, and chromatin content; and presence of binucleated or multinucleated cells) are notoriously unreliable for assessing the growth of such tumors. In the majority of biopsy specimens mitoses are either absent or very rare.l '9 A monoclonal antibody (Ki-67) developed by Gerdes and collaborators 6 that recognizes a proliferation-associated nuclear antigen has greatly facilitated the determination of the growth rate of human neoplasms. 2, 4 The antigen is expressed throughout the entire cycle of proliferating normal and neoplastic human cell populations but is absent in resting cells (Go-phase). 5 This study was performed to determine the growth fraction of the various endocrine types of pituitary adenomas.
Clinical Material and Methods
We examined biopsy specimens of 31 pituitary adenomas representing all major endocrine types (Table 1 ) obtained from 17 women and 14 men. The average age of the patients was 43 years (range 16 to 75 years). The average diameter of the tumors was 24 mm (range 3 to 50 mm). The adenomas were extirpated by the transsphenoidal approach. Frozen tissue sections and cytological smears were immunostained with the Ki-67 monoclonal antibody. 2,4 Fresh tissue was obtained from 26 of these patients and, immediately after removal, was frozen in a beaker of isopentane suspended in liquid nitrogen; it was then removed from the isopentane and immersed directly in liquid nitrogen for intervals of up to 3 weeks. Air-dried acetone-fixed squash preparations were obtained from 21 adenomas. Dried cryostat sections and dry cytological smears were incubated with the undiluted monoclonal antibody Ki-67.* The antibody was visualized with the peroxidase-antiperoxidase method. Harris' hematoxylin was used as counterstain. The Ki-67 immunoreative nuclei as well as mitoses were counted on representative photographs depicting 1000 to 2000 adenoma cell nuclei, and percentages were calculated. 
R e s u l t s
All adenomas examined contained Ki-67-positive cell nuclei (Table 1 and Fig. 1 ). The results of Ki-67 expression obtained with the two preparation methods (frozen sections vs. smears) showed a good correlation of the values obtained from the individual patients (Fig.  2 ). The mean value was used for further evaluation if minor differences existed.
The incidence of Ki-67-positive nuclei, however, varied markedly, with rather low values being present in the group without clinical signs of endocrine activity (Table 1) . Significantly higher values, with an astonishingly small variation, were present in six adenomas causing acromegaly. Prolactinomas demonstrated the greatest variation, with values covering the entire range observed. A comparison of Ki-67 immunoreactivity with sex and age of the patients, tumor diameter (in the entire group and in the endocrine subgroups), and serum levels of the abnormally secreted hormones did not reveal significant correlations. The Ki-67 immunoreactivity of 12 prolactinomas examined was not influenced by preoperative bromocriptine treatment (Table 2 ).
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only very few were seen in each case. The highest value was 1.0% of the cell nuclei ( Table 3 ). The nuclear antigen reacting with Ki-67 was localized on the chromosomes during all phases of the mitosis (Fig. 3) .
Histological examination of the excised dura covering the sella floor demonstrated invasive growth in 20 of 30 adenomas examined. Surgical observation and preoperative computerized tomography (CT) were not as sensitive as Ki-67 expression in detecting invasive growth ( Table 4 ). The average rate of Ki-67 expression for sella dura was 0.55% (range 0.1% to 1.4%) in histologically noninvasive and 1.19% (range 0.2% to 3.7%) in histologically invasive adenomas. The two groups differed significantly (p < 0.1 in Wilcoxon's rank-order test), indicating that invasive adenomas have a higher growth fraction than noninvasive adenomas. No significant differences of Ki-67 expression were found in invasive and noninvasive adenomas as observed during surgical intervention and on preoperative CT because invasive growth, particularly if only microscopic, was frequently missed with the latter two methods of observation. Only one case with normal dura histology demonstrated invasive growth on CT and during surgical exposure.
Discussion
In pituitary adenomas, the percentage of proliferating cells (equivalent to the cell growth fraction) that are known for their slow growth is astonishingly high. It equals values found in benign intracranial tumors (astrocytomas, oligodendrogliomas, ependymomas, and meningiomas). 2 The finding of 1.2% to 1.5% proliferating cells in five adenomas with diameters of only 8 to 1l m m causing acromegaly in patients with retro- Difference not significant.
spective histories of abnormal body growth for 5 to 10 years suggests that the cell proliferation observed was only marginally higher than the naturally occurring cell loss. Macroscopic or microscopic invasion into the surrounding structures was found in 50% to 94% of the pituitary adenomas examined. Invasion occurs more frequently in macroadenomas than in microadenomas. m'13 Invasive adenomas have a significantly larger growth fraction than noninvasive adenomas as shown by our study. However, long-term follow-up studies will be required to determine the importance of this finding because the prognostic and possibly therapeutic significance of invasive growth, particularly microinvasion, remains to be determined. suggested that bromocriptine may inhibit DNA synthesis. Their evidence was based on only three bromocriptine-treated patients, however, and the differences observed were not significant. In the present series, the growth rate was not influenced by preoperative bromocriptine treatment (Table 2) . Bromocriptine-treated patients either had received their last dose in the evening before surgery or had recently received an intramuscular injection of a new long-acting form of the drug. ~J An uncontrolled drug-free preoperative interval therefore cannot be responsible for this lack of a significant difference (p > 0.1 in Wilcoxon's rank-order test). Our data do not seem to be in agreement with an experimental study by Johansen, et al., 8 who used cultures of a highly differentiated cell line (GH3) obtained from a rat pituitary tumor incubated with bromocriptine; that study demonstrated a dose-dependent delay of the cell cycle with a reduction of the cell growth rate. However, the bromocriptine concentration of the tissue culture fluid used was seven to 70 times higher than the serum levels measured in bromocriptine-treated patients. 3' 1 ~,14
In conclusion, these results show that the determination of Ki-67 immunoreactivity (equivalent to the tumor growth fraction) in the cell nuclei of pituitary adenomas may be an important tool for rapid intraoperative quantitative assessment of tumor growth, planning of adjuvant therapy, and possibly estimation of prognosis.
